R.H. Investment Group LLC Buys New Shares in Thermo Fisher Scientific Inc. $TMO

R.H. Investment Group LLC purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 9,168 shares of the medical research company’s stock, valued at approximately $4,596,000. Thermo Fisher Scientific accounts for approximately 3.5% of R.H. Investment Group LLC’s portfolio, making the stock its 16th largest holding.

A number of other hedge funds also recently modified their holdings of TMO. North Dakota State Investment Board bought a new position in Thermo Fisher Scientific during the fourth quarter worth about $7,505,000. Hudson Value Partners LLC lifted its position in shares of Thermo Fisher Scientific by 24.9% during the 2nd quarter. Hudson Value Partners LLC now owns 16,653 shares of the medical research company’s stock worth $8,349,000 after buying an additional 3,317 shares during the period. Boston Trust Walden Corp boosted its stake in Thermo Fisher Scientific by 9.7% in the 4th quarter. Boston Trust Walden Corp now owns 43,973 shares of the medical research company’s stock valued at $25,480,000 after buying an additional 3,873 shares in the last quarter. Xponance LLC lifted its holdings in shares of Thermo Fisher Scientific by 8.1% during the fourth quarter. Xponance LLC now owns 59,295 shares of the medical research company’s stock valued at $34,358,000 after acquiring an additional 4,436 shares during the period. Finally, Annex Advisory Services LLC boosted its stake in shares of Thermo Fisher Scientific by 12.6% in the 2nd quarter. Annex Advisory Services LLC now owns 24,656 shares of the medical research company’s stock valued at $12,361,000 after purchasing an additional 2,756 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $574.47, for a total value of $5,744,700.00. Following the transaction, the chief executive officer owned 123,925 shares in the company, valued at $71,191,194.75. This trade represents a 7.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the sale, the executive vice president directly owned 20,994 shares of the company’s stock, valued at $12,596,400. This represents a 54.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 52,053 shares of company stock valued at $30,643,589 over the last ninety days. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.8%

Shares of NYSE TMO opened at $590.00 on Wednesday. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $643.99. The company has a 50-day moving average of $533.64 and a two-hundred day moving average of $508.36. The company has a market cap of $218.15 billion, a PE ratio of 31.74, a P/E/G ratio of 2.39 and a beta of 0.84. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. During the same period in the prior year, the firm earned $4.28 earnings per share. Thermo Fisher Scientific’s revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.11%.

Analyst Ratings Changes

TMO has been the subject of a number of recent analyst reports. Royal Bank Of Canada increased their target price on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a research report on Friday, July 24th. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Jefferies Financial Group reiterated a “buy” rating and issued a $630.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Evercore set a $570.00 price target on Thermo Fisher Scientific in a research report on Monday, July 6th. Finally, Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They set a “market perform” rating and a $520.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $619.41.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.